Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleSpecial Communications

Cannabis and Its Derivatives: Review of Medical Use

Lawrence Leung
The Journal of the American Board of Family Medicine July 2011, 24 (4) 452-462; DOI: https://doi.org/10.3122/jabfm.2011.04.100280
Lawrence Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    Table 1.

    Clinical Studies of Cannabis and Its Derivatives with SORT Level of Recommendation56

    AgentCondition IndicatedForm of deliveryNature of StudyPatients (n)Outcome MeasuresOutcomeSORT Level of RecommendationReference
    CannabisGilles de la Tourette SyndromeSmokingCase report3Self-reported frequency of motor tics50% to 70% remissionCSandyk et al57
    CannabisGilles de la Tourette SyndromeSmokingCase report1Self-reported symptoms100% remissionCHemming et al58
    CannabisGlaucomaSmoking single doseDouble-blinded cross-over placebo-controlled RCT18Intraocular pressureSignificant reductionBMerritt et al59
    CannabisNeuropathic pain in HIV patientSmoking 5 days a week for 2 weeksProspective placebo-controlled RCT28Pain intensity using Descriptor Differential ScaleImprovement in pain (P = .016)AEllis et al49
    CannabisSensory neuropathic pain in HIV patientSmoking 3 times a day for 5 daysDouble-blinded cross-over placebo-controlled RCT50Chronic pain ratingsReduction of pain by 34% (P = .03)AAbrams et al48
    CannabisCapsaicin-induced pain in volunteersSmoking single dose at various concentrationsDouble-blinded cross-over placebo-controlled RCT15Pain scores and McGill Pain QuestionnairePain reduction at medium dose within a certain time frame onlyBWallace et al60
    CannabisAcute inflammatory pain in volunteersSingle oral dose of encapsulate extractDouble-blinded cross-over placebo-controlled RCT18Threshold to heat and electricity in areas with UV-induced sunburntNo effect on pain thresholdsBKraft et al61
    CannabisSpasticity due to multiple sclerosisEscalating dose of oral encapsulate extractDouble-blinded cross-over placebo-controlled RCT50Spasms frequency and mobilityImprovement in spasms frequency (P = .013) and mobility (P = .01)AVaney et al62
    CannabisSpasticity caused by multiple sclerosisTitrating oral dose of cannabis extractDouble-blinded placebo-controlled RCT327Ashworth score and self-reported spasticityImprovement of self-report ratings of pain and spasticity (P = .003)AZajicek et al63
    Δ9-THCGilles de la Tourette SyndromeSingle oral doseCross-over placebo-controlled RCT12TSSL, STSS, YGTSS scoresSignificant reduction in TSSL score (P = .015), nil for STSS and YGTSSAMüller-Vahl et al64
    Δ9-THCGilles de la Tourette SyndromeDaily oral dose for 6 weeksPlacebo-controlled RCT24TSSL,TS-CGI, STSS; YGTSSSignificant reduction in TSSL score using ANOVA (P = .037), nil for TS-CGI, STSS, YGTSSAMüller-Vahl et al65
    Δ9-THCSpasticity caused by multiple sclerosisEscalating dose for 5 daysDouble-blinded cross-over placebo-controlled RCT13Subjective rating and objective measure of spasticitySignificant in both scoresAUngerleider et al66
    Δ9-THCSpasticity due to multiple sclerosisTitrating oral dose of Δ9-THCDouble-blinded placebo-controlled RCT330Ashworth score and self-reported spasticityImprovement of self-report ratings of pain and spasticity (P = .003)AZajicek et al63
    Δ9-THCPostoperative painSingle oral dose on postoperative day 2Double-blinded placebo-controlled RCT40Summed pain intensity difference 6 hours after administrationNo significant differenceBBuggy et al67
    Δ9-THCRefractory neuropathic painTitrating oral doseOpen label pilot8Neuropathic pain score and quality of lifeNo apparent effectCAttal et al68
    Δ9-THCGlioblastoma multiformeDaily intracranial tumour injection up to 64 daysPhase I cohort pilot study9Safety of intracranial route of administrationIntracranial route seems to be safe and may slow down tumour growthCGuzman et al69
    Dronabinol (synthetic Δ9-THC)Alzheimer’s diseaseTwice-daily oral dose for 6 weeksDouble-blinded cross-over placebo-controlled RCT15Body weight, triceps skin fold, disturbed behavior, affectA trend of improvement reported but no significance quotedBVolicer et al70
    Dronabinol (synthetic Δ9-THC)Alzheimer’s diseaseDaily oral dose for 2 weeksOpen label pilot6Nocturnal motor activity score and Neuropsychiatric InventorySignificant improvement in both (P = .028 and P = 0027)CWalther et al71
    Dronabinol (synthetic Δ9-THC)Anorexia and weight loss in AIDSTwice-daily oral dose for 6 weeksPlacebo-controlled RCT139VAS for appetite, mood, and nauseaSignificant change in appetite (38%; P = .015); mood (10%; P = .06); and nausea (20%; P = .05)ABeal et al72
    NabiloneSpasticity caused by spinal cord injuryTwice-daily oral dose for 4 weeksDouble-blinded cross-over placebo-controlled RCT12Ashworth Scale, Total Ashworth ScoreSignificant reduction, P = .003 and 0.001 respectivelyAPooyania et al73
    NabilonePain caused by fibromyalgiaOral dose for 4 weeksDouble-blinded placebo-controlled RCT40VAS and Fibromyalgia impact questionnaireSignificant reduction in both scores (P < .02)ASkrabek et al74
    Sativex (extract of cannabis containing Δ9-THC and cannabidiol)Peripheral neuropathic painSelf-titrating dose of oromucosal spray for 5 weeksDouble-blinded placebo-controlled RCT125Various pain intensity scoresSignificant reduction, (P = .001 to P = .04)ANurmikko et al75
    Sativex (extract of cannabis containing Δ9-THC and cannabidiol)Intractable neurogenic symptomsSelf-titrating dose of oromucosal spray for 2 weeksDouble-blinded cross-over placebo-controlled RCT20Self-report symptoms and adverse effectsSignificant relief in pain with certain domains reaching significance of P < .05AWade et al76
    Sativex (extract of cannabis containing Δ9-THC and cannabidiol)Central pain in multiple sclerosisSelf-titrating dose of oromucosal spray for 4 weeksDouble-blinded placebo-controlled RCT6611-point scale for pain and sleep disturbanceSignificant reduction of pain (P = .005) and sleep disturbance (P = .003)ARog et al77
    Sativex (extract of cannabis containing Δ9-THC and cannabidiol)Bladder dysfunction in multiple sclerosisSingle daily dose for 8 weeksOpen label pilot study15Occurrence of urinary incontinence, frequency, nocturiaSignificant reduction in all 3 domains (P < .05)ABrady et al78
    • RCT, randomized controlled trial; UV, ultraviolet; TSSL,; STSS,; YGTSS,; TS-CGI, ANOVA, analysis of variance; VAS, Visual Analog Scale; THC, tetrahydrolcannabinol.

PreviousNext
Back to top

In this issue

The Journal of the American Board of Family Medicine: 24 (4)
The Journal of the American Board of Family Medicine
Vol. 24, Issue 4
July-August 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cannabis and Its Derivatives: Review of Medical Use
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Cannabis and Its Derivatives: Review of Medical Use
Lawrence Leung
The Journal of the American Board of Family Medicine Jul 2011, 24 (4) 452-462; DOI: 10.3122/jabfm.2011.04.100280

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cannabis and Its Derivatives: Review of Medical Use
Lawrence Leung
The Journal of the American Board of Family Medicine Jul 2011, 24 (4) 452-462; DOI: 10.3122/jabfm.2011.04.100280
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case 1
    • Case 2
    • The Laws Regarding Cannabis
    • The Harms of Cannabis
    • New Kids on the Block
    • Analgesic Potential and Synergism With Opioids
    • Evidence from Clinical Studies
    • The Challenges of Using Cannabis
    • The Controversy Remains
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • KLS-13019, a Novel Structural Analogue of Cannabidiol and GPR55 Receptor Antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy in Rats
  • Individual and combined effects of Cannabidiol (CBD) and {Delta}9-tetrahydrocannabinol (THC) on striato-cortical connectivity in the human brain
  • The Most Frequently Read Articles of 2019
  • Content Usage and the Most Frequently Read Articles of 2018
  • Recreational Marijuana Use: Is it Safe for Your Patient?
  • Content Usage and the Most Frequently Read Articles by Issue in 2011
  • In this Issue: Testing Characteristics of Patient-Centered Medical Homes, Patient Self-Care, Predicting Outcomes, and Practical Clinical Information
  • Google Scholar

More in this TOC Section

  • Integrating Community and Clinical Data to Assess Patient Risks with A Population Health Assessment Engine (PHATE)
  • Primary Care Is an Essential Ingredient to a Successful Population Health Improvement Strategy
  • Hepatitis C Update and Expanding the Role of Primary Care
Show more Special Communications

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire